Outcomes of patients with Killip class III acute myocardial infarction after primary percutaneous coronary
Tzu-Hsien Tsai1, Sarah Chua, Hisham Hussein
1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.
Insights
Patients with Killip class III acute ST-segment elevation myocardial infarction (STEMI) face significantly higher mortality risks, even after primary percutaneous coronary intervention. Killip III status is an independent predictor of both 30-day and 1-year mortality in STEMI patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Acute Myocardial Infarction Research
Background:
- Outcomes for patients with Killip class III acute ST-elevation myocardial infarction (STEMI) in the reperfusion era are not well-established.
- Primary percutaneous coronary intervention (PCI) is a standard treatment for STEMI, but its impact on high-risk patient subgroups requires further investigation.
Purpose of the Study:
- To investigate the short- and long-term outcomes of patients with Killip class III STEMI who underwent primary PCI.
- To determine if Killip class III remains an independent predictor of mortality in the current treatment paradigm.
Main Methods:
- A prospective study of 1,278 consecutive STEMI patients undergoing primary PCI between January 2002 and November 2009.
- Patients were categorized into Killip class I (n=832), II (n=216), and III (n=230) based on presentation.
- Outcomes including angiographic findings, in-hospital complications, and 30-day and 1-year mortality were analyzed.
Main Results:
- Killip III patients had significantly lower final thrombolysis in myocardial infarction (TIMI) 3 flow and higher incidence of multi-vessel disease compared to Killip I and II.
- The incidence of advanced congestive heart failure during hospitalization was substantially higher in Killip III patients (71.3%).
- 30-day mortality (20.0%) and 1-year cumulative mortality (31.7%) were significantly higher in Killip III patients, who were independently predicted by this classification.
Conclusions:
- Killip class III remains a strong and independent predictor of 30-day and 1-year mortality in STEMI patients, despite undergoing primary PCI.
- These findings highlight the critical need for aggressive management and closer monitoring of STEMI patients presenting with Killip class III.
- Further research may explore novel therapeutic strategies to improve outcomes in this high-risk population.
Objectives:
Little is known about the outcomes of patients with Killip class III acute ST-segment elevation myocardial infarction in the reperfusion era. This study investigated the short- and long-term outcomes of these patients who underwent primary percutaneous coronary intervention.
Methods:
Between January 2002 and November 2009, a total of 1,278 consecutive patients with acute ST-segment elevation myocardial infarction underwent primary percutaneous coronary intervention. Of these patients, 230 (17.0%) with Killip III, 216 (16.9%) with Killip II, and 832 (65.1%) with Killip I upon presentation were prospectively recruited.
Results:
Angiographic study showed significantly lower final thrombolysis in myocardial infarction 3 flow in patients with Killip III compared with those with Killip II and I (83.5% vs. 94.9% vs. 95.7%, p<.0001). The incidence of multiple vessel disease was also notably higher in Killip III than in Killip II and I (65.7% vs. 13.9% vs. 53.8%, p<.001). Besides, the incidence of advanced congestive heart failure (defined as greater than or equal to New York Heart Association functional class 3) during hospitalization was remarkably higher in Killip III compared to Killip II and I (71.3% vs. 13.9% vs. 6.6%, p<.001). Furthermore, the 30-day mortality and 1-yr cumulative mortality were notably higher in Killip III than in Killip II and I (20.0% vs. 4.2% vs. 1.7%, p<.001 and 31.7% vs. 7.9% vs. 4%, p<.001, respectively). Multivariate analysis showed that Killip III was independently predictive of 30-day and 1-yr mortality (all p < .04).
Conclusion:
Killip III remains strongly and independently predictive of 30-day and 1-yr mortality in ST-segment elevation myocardial infarction patients even undergoing primary percutaneous coronary intervention.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Peripheral Artery Disease III: Interprofessional Care
Endocarditis IV: Nursing Management
Endocarditis III: Medical Management
Myocarditis III: Medical Management

